Relia Tech/Human B7-H2 Fc/100 µg/100-017
市场价：
¥3400.00
美元价：
2040.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Cat-Nr. | 100-017 |
| Size | 100 µg |
| Price | 170 € |
| Source | CHO cells |
| Label | Fc-tag |
| Formulation | lyophilized |
| Purity Confirmation | > 95% by SDS-PAGE & HPLC analyses |
| Length [aa] | 471 |
| Molecular Weight | 104.9 kDa |
| Endotoxin Levels | < 0.1 ng/µg of protein (<1EU/µg) |
| Biological Activity | Determined by its ability to induce adhesion in Jurkat cells activated by immobilized anti-CD3. The ED50 for this effect is 0.3-0.6 μg/ml. |
| Species Reactivity | Human |
| Synonyms | Inducible Costimulator-Ligand (ICOSL), B7 homolog 2, B7-like protein Gl50, B7-related protein 1 (B7RP-1), CD276 |
| Description | B7-H2, or inducible costimulator-ligand (ICOSL), is a transmembrane, co-stimulatory ligand of the T cell-specific surface receptor Inducible T-cell costimulator (ICOS) that belongs to the B7 family and immunoglobulin superfamily, along with B7-1, B7-2, PD-L1 (B7-H1) and PD-L2. Whereas expression of inducible B7-1 and B7-2 is largely confined to specialized antigen-presenting cells of lymphoid tissues, B7-H2 expression occurs constitutively in hematopoietic and non-hematopoietic cells of peripheral organs. This striking difference in expression indicates that these three B7 ligands may enable temporally and spatially specific regulation of T cell response through non-competitive CD28 interaction; marking a unique function of B7-H2 in immune reactions of nonlymphoid organs in which T cells have migrated to peripheral tissues having only limited expression of B7-1 and B7-2. Expression of B7-H2 has been shown to be differentially regulated by both TNF-α and IL-1β, and inducible to a lesser extent by CD40 or lipopolysaccharide stimulation. B7-H2’s binding to ICOS on activated T cells results in both positive and negative effects on immune response, including its own downregulation. As a member of the immunoglobulin superfamily, B7-H2 is crucially involved in inflammatory immune reactions and the control of excessive immune response; however, unlike B7-1 and B7-2, B7-H2 has not been shown to influence immunity through interaction with CTLA-4, and has only been shown to have restricted interaction with CD28. Interaction of B7-H2 with ICOS has been identified as a critical event in the immunosuppression of tumor-associated memory CD4+ T cells, and has been linked to various auto-immune disorders. Recombinant Human B7-H2 Fc is a glycosylated, disulfide-linked homodimer of 942 amino acid residues whose monomer consists of the 238-amino-acid length extracellular portion of B7-H2 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of Recombinant Human B7-H2 Fc dimer is 104.9 kDa; however, due to glycosylation, it migrates at an apparent molecular weight of approximately 90-95 kDa by SDS-PAGE analysis under reducing conditions. |
| Protein Sequence | DTQEKEVRAM VGSDVELSCA CPEGSRFDLN DVYVYWQTSE SKTVVTYHIP QNSSLENVDS RYRNRALMSP AGMLRGDFSL RLFNVTPQDE QKFHCLVLSQ SLGFQEVLSV EVTLHVAANF SVPVVSAPHS PSQDELTFTC TSINGYPRPN VYWINKTDNS LLDQALQNDT VFLNMRGLYD VVSVLRIART PSVNIGCCIE NVLLQQNLTV GSQTGNDIGE RDKITENPVS TGEKNAATGG PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K |
| Uniprot ID | O75144 |
| Protein RefSeq | NP_056074.1 |
| mRNA RefSeq | NM_015259.5 |
品牌介绍
Receptor Ligand Technologies GmbH 公司（RELIA Tech ）位于德国不伦瑞克，是一家后基因组生物技术公司，该公司运用独特的技术专注于受体和配体的发现与研究，从而使商业化，产品广泛使用于科学研究，实验诊断和临床应用。瑞莱技术的灵活性和竞争力必将使其在这个快速整合的功能基因组学和蛋白组学的新时代发展壮大.RELIA公司提供的细胞因子，生长因子，重组蛋白产品一致内毒素检测项目，且内毒素水平非常低。 受体配体技术有限公司（RELIATech）是一家后基因组生物技术公司，致力于在配体与受体相互作用领域的新技术和新产品的发现和商业化，用于研究，诊断和临床领域。该公司位于德国不伦瑞克，由以下公司成立于2000年10月： 阿夫纳·亚永教授以色列魏兹曼科学研究所（WIS） 赫伯特·韦奇博士德国生物技术德国研究中心（GBF） Bernhard Barleon博士德国肿瘤生物学诊所（KTB） 创始人是从事细胞生长因子相互作用，酪氨酸激酶及其信号传导途径（涉及组织重塑，体内平衡和疾病）领域的细胞和分子生物学家，工作时间超过10年。特别是Herbert A. Weich博士和Bernhard Barleon博士从事血管生成，肿瘤血管生成和实体瘤进展领域的基础研究。 诸如“生长因子和细胞因子”之类的信号蛋白，连同其跨膜/“可溶性受体”和相关的激酶，在生理和病理生理条件下都作为关键的调节分子参与了所有高级生物的发育和功能。这些多肽调节细胞分化，组织重塑和体内平衡，并在各种疾病状态下被失调。由人类基因组计划编码新信号蛋白的新生长调节基因的发现，以及对它们功能的阐明，无疑将是未来十年的主要挑战之一。 RELIATech的使命是开发和商品化在“受体和配体相互作用”领域中有用的新产品，用于基础研究，药物开发和临床社区。RELIATech的灵活性和能力必将使其在功能基因组学和蛋白质组学的新时代迅速整合和扩展。
联络我们
